Supporting data for Mirabegron activates energy expenditure in human induced pluripotent stem cell (hiPSC)-derived beige adipocytes via a self-driven loop of the acetylcholine-acetylcholine receptor

Modern people are exposed to an ever-increasing number of calories resulting in increasing obesity and related metabolic diseases. With the considerable developments in obese treatment, the differentiation ability of pluripotent embryonic stem (ES) cells makes it possible to be a potentially useful tool for disease modeling and therapeutic screening. Mirabegron is an FDA-approved drug to treat an overactive bladder by specifically activating the beta 3 adrenergic receptor. Recently it is found that people administered Mirabegron showed increased activity of thermogenic adipose tissue but the detailed mechanism is unclear. 

This dataset almost includes all the experiments in the project.  We generated human beige adipocytes from induced pluripotent stem cells (iPSCs), one kind of pluripotent cells with extended differentiation ability. The effects of mirabegron on EPSC-derived beige adipocytes were examined by Seahorse, glucose uptake studies. The cells were subjected to RNASeq and ATAC-Seq analysis. Glucose uptake was examined by 6-NBOG uptake and flow cytometry.

现代人类面临着日益增长的卡路里摄入，导致肥胖及相关代谢性疾病的发病率上升。随着肥胖治疗领域的显著进展，多能胚胎干细胞（ES细胞）的分化能力使得其成为疾病建模和治疗方案筛选的潜在有用工具。米拉贝隆（Mirabegron）是一种经美国食品药品监督管理局（FDA）批准的药物，通过特异性激活β3肾上腺素能受体来治疗过度活跃的膀胱。近期研究发现，接受米拉贝隆治疗的患者表现出增加的产热脂肪组织活性，但其详细机制尚不明确。本数据集几乎包含了项目中的所有实验。我们通过诱导多能干细胞（iPSCs）生成人类米色脂肪细胞，这是一种具有扩展分化能力的多能细胞。通过Seahorse和葡萄糖摄取研究等方法，考察了米拉贝隆对EPSC来源的米色脂肪细胞的影响。细胞进行了RNA测序（RNASeq）和ATAC测序（ATAC-Seq）分析。葡萄糖摄取通过6-NBOG摄取和流式细胞术进行检测。